Scientists have identified how the hormone FGF21 reverses obesity in mice by activating a specific brain circuit tied to metabolism.
The research, conducted by University of Oklahoma scientists and published in Cell Reports, shows FGF21 signals to the hindbrain — the same region targeted by GLP-1 drugs like Ozempic — but through a different mechanism that increases energy expenditure rather than suppressing appetite.
This discovery reveals a potential pathway for new weight-loss therapies that could avoid the gastrointestinal side effects and bone loss associated with current FGF21 analogues in development.
FGF21 acts through the hindbrain to boost metabolism
Lead researcher Matthew Potthoff and his team found that FGF21 interacts with two specific structures in the hindbrain: the nucleus of the solitary tract and the area postrema. These regions then signal to the parabrachial nucleus, forming a neural circuit essential for the hormone’s metabolic effects.
This pathway was unexpected, as earlier assumptions pointed to the hypothalamus as the primary site of FGF21 action in weight regulation. The hindbrain’s role in mediating FGF21’s influence on fat burning distinguishes it from the appetite-suppressing mechanism of GLP-1 receptor agonists.
Current FGF21-based drugs face side effect challenges
Even as pharmaceutical companies are testing FGF21 analogues in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH), these compounds have shown adverse effects including gastrointestinal distress and, in some cases, bone loss.
By pinpointing the exact brain circuit through which FGF21 operates, researchers aim to design more precise therapies that retain metabolic benefits while minimizing unintended consequences.
Previous research highlighted brain-liver signaling gaps
In earlier work, Potthoff’s team established that FGF21 signals to the brain rather than directly to the liver to improve metabolic function, but the exact neural targets remained unidentified until this study.
How does FGF21 differ from GLP-1 medications in its action on the brain?
FGF21 increases metabolic activity and energy burning, while GLP-1 drugs reduce appetite and food intake, even though both affect overlapping regions of the hindbrain.
What conditions are FGF21-based therapies currently being tested for?
FGF21 analogues are in clinical trials for MASH, a severe form of fatty liver disease characterized by inflammation and liver fibrosis.